Oculis Aktie
| 19,28USD | -0,81USD | -4,03% | 
WKN DE: A3D8QG / ISIN: CH1242303498
Personal
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Personal am Ende des Jahres | 2 | 28 | 36 | 49 | 
| Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,00 | 0,00 | 
Bilanz (in Mio. USD) - Aktiva
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Summe Umlaufvermögen | 1 | 26 | 120 | 116 | 
| Summe Anlagevermögen | 128 | 14 | 16 | 17 | 
| Summe Aktiva | 128 | 40 | 136 | 133 | 
Bilanz (in Mio. USD) - Passiva
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Summe Fremdkapital | 8 | 146 | 25 | 52 | 
| Summe Eigenkapital | 121 | -106 | 111 | 81 | 
| Summe Passiva | 128 | 40 | 136 | 133 | 
Adresse
| Bahnhofstrasse 20, 6300 Zug | |
| Telefon | +41 (41) 711-39-60 | 
| Internet | http://www.oculis.com | 
Management
| Anthony Adam Rosenberg Chairman | 
| Arshad M. Khanani Director | 
| Caroline Daniere Chief Human Resources Officer | 
| Christina Maria Ackermann Independent Non-Executive Director | 
| Geraldine O'Keeffe Independent Director | 
| Gudrun Bachmann Chief Technology Officer | 
| Isabelle de Chambrier Chief Quality Officer | 
| Lionel Carnot Independent Director | 
| Martijn Kleijwegt Independent Director | 
| Páll Ragnar Jóhannesson Chief Business Officer | 
| Rebecca Weil Chief Commercial Officer | 
| Riad Sherif Chief Executive Officer & Director | 
| Robert K. Warner Director | 
| Sharon Klier Chief Development Officer | 
| Snehal Shah President-Research & Development | 
| Sylvia Cheung Chief Financial Officer | 
 
									 
									 
								